Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 3 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 41 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
Sartorius Xpress Biologics from Herstal, company number BE0550686915, closed financial year 2025 with a result of € -6.5 million after tax. For that financial year Sartorius Xpress Biologics recorded revenue of € 2.4 million and equity of € -9.5 million. Compared with financial year 2024, the result moved from € -2.2 million to € -6.5 million. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on April 13, 2026.
€ -9.5 million
▼ € 6.7 million vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -6.5 million
▼ 195 % more loss than in 2024
Profit after tax over the fiscal year.
€ 0
▼ 100% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -14.2 million.
People and assets in 2025
76.2
▲ 4.7 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 5.9 million
▲ 16% vs 2024
€ 77,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 391,755
▲ 294% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 14 million
▲ 75% vs 2024
Loans from banks and other lenders, long and short.
€ 773,208
▲ 2% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 40 days on average.
€ 1 million
▲ 19% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 1,008,591 | € 1,852,011 | € 3,605,368 | € 2,406,103 | ▼ 33% |
| Gross margin | € 2,273,477 | - | - | - | |
| Profit after taxes | € -870,098 | € -4,160,856 | € -2,200,900 | € -6,501,258 | ▼ € 4.3 million |
| Equity | € 279,849 | € -482,299 | € -2,828,170 | € -9,487,789 | ▼ € 6.7 million |
| Total debts | € 8,861,274 | € 10,594,370 | € 14,485,225 | € 20,392,205 | ▲ 41% |
| Cash | € 139,620 | € 449,712 | € 177,268 | € 0 | ▼ 100% |
| Retained profit | € -1,334,189 | € -5,495,045 | € -7,695,945 | € -14,197,203 | ▼ € 6.5 million |
| Bank debt | € 4,587,662 | € 7,146,290 | € 8,000,000 | € 14,000,000 | ▲ 75% |
| Balance sheet total | € 9,141,123 | € 10,112,071 | € 11,657,055 | € 10,920,916 | ▼ 6% |
| Employees (FTE) | 37.7 | 62.2 | 71.5 | 76.2 | ▲ 4.7 |
Key figures of Sartorius Xpress Biologics, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Sartorius Xpress Biologics?
What happened at Sartorius Xpress Biologics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Cédric VOLANTI stepped down as director. NBB
- Franck BACKERS stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 6.5 million. Source: NBB ↗
- Cédric VOLANTI became a director. NBB
- Jonas Skjødt MOLLER stepped down as director. NBB
- Jonas Skjødt MOLLER became a director. NBB
- Franck BACKERS became a director. NBB
- New establishment in Herstal. KBO
In short
From € 870,098 loss in 2022 to € 6.5 million loss in 2025.
On average € 60,300 of value added per employee in 2022.
Pays suppliers within 40 days on average.
A new publication or filing at Sartorius Xpress Biologics? We notify you, reason included.
Follow Sartorius Xpress BiologicsDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of BioCompliance Services comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
Sartorius Xpress BiologicsThe shares are held by XpressBioX SRL (100%) and BioCompliance Services (2%). It owns 100% of SARTORIUS ACCESSIA PHARMA itself.
Directors
According to the 2025 annual accounts
since 2025 · until 2031
since 2024 · until 2025
since 2024 · until 2030
Shareholders
Participations
Establishments
Establishment units
Physical locations of this company
Avenue du Parc Industriel 89
4041 Herstal
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Certifications & Partners
Hosting & Email
Email provider
Microsoft 365
Hosting
BABIEL-NET, DE
Domain
Domain
sartorius.com
Registered
1996-07-15
Registrar
EuroDNS S.A.
Expires
2026-07-14
Website info
Features
Security
Details
- Company number
- 0550.686.915
- VAT number
- BE 0550.686.915
- Registered office
- Avenue du Parc Industriel 89, 4041 Herstal
- Names & denominations
- Sartorius Xpress Biologics
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 16 April 2014
- Peppol
- Active · Active since 25 Jun 2026
- Contact
- sartorius.com
- Activities · NACE
Vervaardiging van farmaceutische grondstoffen
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige technische testen en toetsen
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering